Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.

Molecular cancer therapeutics - 1 Aug 2012

Landau Heather J, McNeely Samuel C, Nair Jayasree S, Comenzo Raymond L, Asai Takashi, Friedman Hillel, Jhanwar Suresh C, Nimer Stephen D, Schwartz Gary K

Abstract excerpt

DNA cross-linking agents are frequently used in the treatment of multiple myeloma-generating lesions, which activate checkpoint kinase 1 (Chk1), a critical transducer of the DNA damage response. Chk1 activation promotes cell survival by regulating cell-cycle arrest and DNA repair following genotoxic stress. The ability of AZD7762, an ATP-competitive Chk1/2 inhibitor to increase the efficacy of the DNA-damaging...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Cycle
Share to Checkpoint Kinase 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Micronuclei, Chromosome-Defective

Share to Multiple Myeloma

Share to Protein Kinases

Share to Thiophenes

Source

Identifiers

PMID: 22653969
DOI: 10.1158/1535-7163.MCT-11-0949

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The checkpoint kinase inhibitor AZD7762 potentiates chemotherapy-induced apoptosis of p53-mutated multiple myeloma cells.PMID 22653969Read ↗

The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo.Semantic proximity Read ↗

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.Semantic proximity Read ↗

Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.Semantic proximity Read ↗

Mitomycin–DNA Adducts Induce p53-Dependent and p53-Independent Cell Death PathwaysSemantic proximity Read ↗

Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor–induced DNA damage in vitro and in vivo in human multiple myeloma cellsSemantic proximity Read ↗

Chk1 inhibition significantly potentiates activity of nucleoside analogs in TP53-mutated B-lymphoid cells.Semantic proximity Read ↗

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.Semantic proximity Read ↗

Histone deacetylase inhibition in combination with MEK or BCL-2 inhibition in multiple myeloma.Semantic proximity Read ↗

Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.Semantic proximity Read ↗

Targeting the Fanconi Anemia/BRCA Pathway Circumvents Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma CellsSemantic proximity Read ↗

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating AgentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.